Cognition Therapeutics has set an October 2026 Type C meeting with the FDA to finalize statistical and analytical specifications for the primary endpoint of a registrational Phase 3 trial of Zervimesine in dementia with Lewy bodies accompanied by psychosis. The nine-month study will randomize participants with hallucinations and delusions to 100 mg once-daily oral Zervimesine or placebo, with psychosis severity as the primary outcome. Phase 2 data reported an 89% slowing of hallucination and delusion progression versus placebo on the neuropsychiatric inventory.
Key Points
- FDA meeting set to finalize Phase 3 primary endpoint specifications
- Phase 2 reported 89% slowing of hallucination, delusion progression
- Nine-month trial: 100 mg oral Zervimesine versus placebo
Longevity Analysis
Psychosis in Lewy body dementia is among the strongest predictors of functional decline, caregiver burden, and institutionalization, yet current management relies largely on antipsychotics that carry significant risk in this population. Selecting neuropsychiatric symptoms rather than global cognition as a registrational endpoint reframes what counts as meaningful benefit in neurodegeneration — treating how the brain constructs perception and awareness as a measurable, modifiable target. For clinicians, the more immediate lever remains reducing the anticholinergic and sedative burden that amplifies these symptoms, while monitoring sleep, autonomic signaling, and visual hallucination patterns as early indicators of trajectory.
Original published by LT Wire.